TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

13 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Multiple sclerosis (MS)

    📍 Washington University in St. Louis · St Louis, MO · Get directions →

    This study involves a Positron Emission Tomography (PET) scan using a new investigational radioactive tracer, \[18F\]-FZTA, to detect inflammation in the brain. The tracer will be tested in healthy younger adults and individuals with Multiple Sclerosis.

    ✓ Study care freeAges 18+Learn more →
  • Lupus (SLE)

    INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use

    Studying how adding anifrolumab to usual care affects lupus in real life

    💵 May compensate

    📍 Research Site · Buenos Aires, · Get directions →

    INTERSTELLAR study will generate critical prospective real-world evidence on the benefits of adding Anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients. The study will use clinical assessments that are relevant for SLE-treating physicians in routine clinical practice, as well as introduce a specific measure for skin manifestations to affirm the potency of anifrolumab in treating SLE-related skin manifestations.

    ✓ Study care freeAges 18+Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    New Heart Imaging Techniques to Evaluate Possible Heart Disease

    Testing new heart imaging to check for possible heart disease

    💵 May compensate

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: \- Imaging tests, such as magnetic resonance imaging (MRI), can provide information about heart and blood vessels. The tests let doctors can see the amount of blood vessel narrowing and vessel wall thickness.

    ✓ Study care freeAges 18–100Learn more →
  • Parkinson's disease

    SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

    Testing a single dose of SER-252 in people with Parkinson’s disease

    💵 May compensate

    📍 Rocky Mountain Clinical Research · Englewood, CO · +3 more US sites · Get directions →

    This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctuations.

    ✓ Study care freePhase 1Ages 40–80Learn more →
  • Lupus (SLE)

    A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

    Testing whether cenerimod added to usual treatment helps adults with active lupus nephritis

    💵 May compensate

    📍 Alloy Clinical Research LLC · Kissimmee, FL · +10 more US sites · Get directions →

    The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

    Testing whether sotagliflozin can slow kidney damage in type 1 diabetes

    💵 May compensate

    📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →

    Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Multiple sclerosis (MS)

    Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

    Testing whether ozanimod is safe and works as a step-down treatment for stable multiple sclerosis

    💵 May compensate

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · +2 more US sites · Get directions →

    A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Prevention of Progression of Prediabetes, Obesity and CV Risk

    Testing ways to stop prediabetes and obesity from getting worse

    💵 May compensate

    📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    Testing maridebart cafraglutide with standard care to reduce heart failure events in obese people

    💵 May compensate

    📍 University of Alabama Saint Vincent's Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE).

    ✓ Study care freePhase 3Ages 18–99Learn more →
  • Parkinson's disease

    Blood Pressure Effects on Cognition and Brain Blood Flow in PD

    Testing how blood pressure in Parkinson’s affects thinking and brain blood flow

    💵 May compensate

    📍 University of California San Diego · San Diego, CA · Get directions →

    Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. Besides causing symptoms that impair movement, PD also causes non-motor symptoms, such as problems thinking and orthostatic hypotension (OH), i.e., low blood pressure (BP) when standing.

    ✓ Study care freeAges 50+Learn more →
  • Migraine / chronic headache

    Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

    Studying real-world results of migraine preventive medicines targeting CGRP

    💵 May compensate

    📍 University of Miami, Miller School of Medicine · Miami, FL · Get directions →

    The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.

    ✓ Study care freeAges 18+Learn more →
  • Heart / cardiovascular disease

    Canagliflozin Targeting Vascular Inflammation

    Testing canagliflozin to reduce blood vessel inflammation in cardiovascular disease

    💵 May compensate

    📍 University of Ottawa Heart Institute · Ottawa, Ontario · Get directions →

    CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD

    Testing how to carry out a plan in people with heart and kidney disease who are waiting for a heart

    💵 May compensate

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    Cardiovascular disease is the leading cause of mortality in the US, accounting for 45% of all deaths. Chronic Heart Failure (CHF) is now understood to be a multi-system disease process involving not only the cardiovascular system but also the renal, neuroendocrine, and immune systems.

    ✓ Study care freeAges 18+Learn more →